Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients.

ABSTRACT:

Background

Sclerostin is an endocrine regulator in chronic kidney disease - mineral and bone disorder (CKD-MBD). Validation of assay comparability and pre-analytical handling is mandatory for establishment of sclerostin as a biomarker.

Methods

Blood samples (serum, EDTA, heparin and citrate plasma) were obtained from 12 hemodialysis (HD) patients after the long dialysis interval. Passing-Bablok regression analysis and Bland-Altman difference plots were used to evaluate the agreement between sclerostin levels measured with two commercially available ELISAs from TECOmedical and Biomedica.

Results

Independent of the sample type, the agreement of the two assays was poor with a strong proportional but no systematic bias. Compared to the TECOmedical assay, the Biomedica tes

SUBMITTER: Mause SF 

PROVIDER: S-EPMC4829955 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature